Add a New Bears Reason

Company: Quest Diagnostics (DGX)
Current price:
Headline: (100 character max)
Analysis:
Cancel
0%
agree
0 votes

  Substantial amount of debt at close of FY2006

At the close of fiscal year 2006, Quest had a substantial amount of debt relative to their assets. They also took out a one-time loan for the acquisition of HemoCue. Without making headway against their debt, Quest may run into trouble maintaining growth and their current businesses.

(100 character max) Cancel
0%
agree
1 votes

  On purely techical basis: Target price of $54.36

This is based on a Sell signal of a Jeanty Sell pattern. See http://www.wikinvest.com/image/LUV_SELL.jpg for a description of the pattern.

Here is the current pattern for DGX:

image:JSP_DGX_9_19_08.jpg

Having looked at the definition of a Jeanty Sell Pattern, you should be able to see the 4 components of a Jeanty Sell Signal and figure out the target price of $54.36.

Checking on this forgotten prediction we have this chart: Image:DGX-9-24-08.jpg The target was reached in 4 bars.

(100 character max) Cancel
0%
agree
1 votes

  Medicare and Medicaid are a threat to revenue and profits

Government payers, such as Medicare and Medicaid, as well as private payers and larger employers may continue to take steps to control the cost, utilization and delivery of healthcare services, including clinical laboratory services which could seriously cut in to Quest’s revenue and profit.

(100 character max) Cancel
0%
agree
1 votes

  FDA regulation of genetic tests could hamper performance

FDA regulation of laboratory-developed tests and/or genetic testing could lead to increased costs and delays in introducing new genetic tests, an important and growing segment of Quest’s business.

(100 character max) Cancel
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki